{"id":"W2301614008","doi":"10.1136/gutjnl-2015-311079","title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","year":2016,"lang":"en","type":"article","venue":"Gut","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":803,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"UCB Pharma; Takeda Pharmaceuticals International; Takeda Oncology; Genentech; Sanofi; Kyowa Hakko Kirin; Ironwood Pharmaceuticals, Incorporated; Celltrion; Wellcome Trust; Danone; Novo Nordisk; Janssen Biotech; Teva Pharmaceutical Industries; Gilead Sciences; Osiris Therapeutics; Celgene; Pfizer; Biogen; GlaxoSmithKline; Shire; IC Design Education Center; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Tillotts Pharma; Amgen; ActoGeniX; Dr. Falk Pharma; Abbott Laboratories","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Adverse effect; Inflammatory bowel disease; Gastroenterology; Placebo; Crohn's disease; Incidence (geometry); Hazard ratio; Surgery; Disease; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009685156,0.0004669266,0.001106412,0.0008994168,0.0001933888,0.001514176,0.000462301,0.000555758,0.001386797],"category_scores_gemma":[0.01168359,0.0002221275,0.001708726,0.0009960808,0.0003154288,0.0007611339,0.0005333951,0.0009073426,0.0002993756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005478126,"about_ca_system_score_gemma":0.000764418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003224937,"about_ca_topic_score_gemma":0.0006290469,"domain_scores_codex":[0.9939504,0.002401426,0.001096946,0.0004473243,0.001910374,0.0001936064],"domain_scores_gemma":[0.9825732,0.00427794,0.01049908,0.0004791847,0.001749808,0.0004207245],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04611758,0.0004302924,0.2534435,0.01032072,0.009970317,0.0003891512,0.0002336632,0.002613944,0.01776225,0.0004493978,0.005486335,0.6527829],"study_design_scores_gemma":[0.008233648,0.05372681,0.8227959,0.003946311,0.01463209,0.005686217,0.0002097927,0.002964727,0.01824589,0.001142903,0.06827711,0.0001386423],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5668507,0.4112569,0.005724046,0.00266936,0.0002895583,0.0006364921,0.006124302,0.0002039928,0.006244673],"genre_scores_gemma":[0.9535807,0.03716063,0.002398192,0.0008221319,0.0005348508,0.0002091081,0.004408921,0.00002708937,0.0008583199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009685156,"threshold_uncertainty_score":0.05122066,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006282906948736122,"score_gpt":0.2369828235608517,"score_spread":0.2306999166121156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}